Trending peptide

Kisspeptin

Also called Kisspeptin-54, KP-54, KP54, Metastin, Metastin (1-54), KISS1 peptide, Kisspeptin-10, KP-10, Metastin 45-54.

Kisspeptin is a natural hormone that acts like a starter switch for the body's reproductive system. It tells a small group of brain cells to send a signal to the pituitary gland. It has been given to volunteers and IVF patients in small, supervised studies. No regulator has approved it as a medicine.

Kisspeptin is not an approved medicine for these uses in most countries. This page explains the science and the law; it does not give dosing, sourcing or usage advice.

How strong is the evidence?

AnecdoteAnimalsHuman trialsApproved
Phase 2. Mid-size trials testing if it works.Native kisspeptin-54 has been tested in small, supervised human studies: physiology studies in healthy volunteers and patients (usually 5 to 40 people), a few small randomised trials, and single-centre phase 2 IVF trials (53 and 60 women, plus a 62-woman randomised second-dose trial) in which one injection triggered egg maturation. A 2025 crossover study tested a nasal spray. There is no phase 3 trial and no regulatory approval for any indication. Repeated dosing has shown loss of response (tachyphylaxis) in women with hypothalamic amenorrhoea. FDA's 2024 review found the evidence insufficient to judge kisspeptin-10 for male hypogonadism, and no published clinical trial of kisspeptin-10 given for more than one day. Popular claims about weight loss, libido or fertility outside these studies are not established by trials.

Last verified 2026-09-29 · how we verify

43. P · Proline7. P · Proline25. R · Arginine32. G · Glycine14. R · Arginine50. F · Phenylalanine54. F · Phenylalanine36. V · Valine18. G · Glycine3. S · Serine21. A · Alanine39. E · Glutamate47. W · Tryptophan29. A · Alanine11. S · Serine28. P · Proline10. S · Serine46. N · Asparagine40. K · Lysine4. L · Leucine22. P · Proline17. P · Proline35. L · Leucine53. R · Arginine51. G · Glycine15. Q · Glutamine33. A · Alanine6. P · Proline24. S · Serine42. L · Leucine8. P · Proline44. N · Asparagine26. Q · Glutamine13. S · Serine31. Q · Glutamine49. S · Serine37. Q · Glutamine1. G · Glycine19. L · Leucine2. T · Threonine20. S · Serine38. R · Arginine48. N · Asparagine30. P · Proline12. G · Glycine9. E · Glutamate27. I · Isoleucine45. Y · Tyrosine41. D · Aspartate5. S · Serine23. H · Histidine34. V · Valine16. Q · Glutamine52. L · LeucineNC

Schematic

  • Glycine or proline
  • Water-loving
  • Water-avoiding
  • Negative charge
  • Positive charge

Schematic from the amino-acid sequence — not an experimental structure

54 amino acids, one bead each, coloured by type, N-terminus to C-terminus. The helix shape is illustrative; it is not the real 3D shape of Kisspeptin.

Acts on
KISS1R (kisspeptin receptor, also called GPR54): a Gq/11-coupled receptor on GnRH neurons; loss-of-function variants cause hypogonadotropic hypogonadism in people, and cryo-EM structures of the receptor bound to kisspeptin-54 and kisspeptin-10 have been solved, GnRH neurons of the hypothalamus: kisspeptin activates them directly (shown in mice and sheep; supported by human genetics and human hormone responses), Pituitary gonadotropes (indirectly): LH and FSH release follows the GnRH signal, shown in human studies
Taken as
Not given by any approved route, because no kisspeptin product is approved anywhere. In published clinical research, kisspeptin-54 has been given by intravenous infusion or bolus and by subcutaneous injection under medical supervision, and intranasally in one 2025 crossover study. Kisspeptin-10 has been studied by intravenous and subcutaneous routes. FDA's 2024 review found no human study of intramuscular kisspeptin-10. The synthetic analogue MVT-602 (previously TAK-448) has been studied by subcutaneous injection.
Half-life
About 28 minutes for kisspeptin-54 in the blood of healthy men (27.6 +/- 1.1 min, intravenous infusion). Kisspeptin-10 is cleared faster, at about 4 minutes.[src]
Discovery
Kisspeptin-54 (metastin) was isolated from human placenta in 2001 as a C-terminally amidated, 54-residue peptide that is the natural ligand of the orphan receptor later called KISS1R/GPR54.[src]
Human genetics
Inactivating mutations in the kisspeptin receptor gene GPR54 cause autosomal recessive isolated hypogonadotropic hypogonadism in people (first reported in 2003).[src]
First human hormone study
In a double-blind crossover of 6 healthy men, a 90-minute kisspeptin-54 infusion raised mean LH from 4.2 to 10.8 U/L; the plasma half-life was 27.6 +/- 1.1 minutes.[src]

Inside the body

What Kisspeptin does, step by step

Watch the 3D journey →
  1. 01Brain

    Kisspeptin cells in the hypothalamus make the hormone

    Deep in the brain, in a region called the hypothalamus, there are special cells that make kisspeptin. Your own body makes it. It helps decide when puberty starts and keeps the reproductive system running.

    For experts

    Two kisspeptin neuron populations project to GnRH neurons. Infundibular (arcuate in rodents) neurons co-express neurokinin B and dynorphin (KNDy neurons) and are thought to shape pulsatile GnRH release. In rodents, a second population in the rostral periventricular area (AVPV) drives the pre-ovulatory LH surge through oestrogen positive feedback; in the human hypothalamus only sparse kisspeptin neurons have been found in the preoptic area. The KNDy picture is also less clear-cut in humans, with little overlap of the three peptides reported in young men. Kisspeptin-54, first isolated from placenta, is the major circulating isoform in humans. Much of the detailed circuitry comes from rodent and primate work, with human data mainly from imaging, genetics and hormone responses.[src][src][src]

  2. 02Brain

    Kisspeptin switches on GnRH cells

    Kisspeptin fits into a matching receptor, like a key in a lock, on brain cells that make GnRH. This turns those cells on. People born with a broken receptor do not go through puberty without treatment.

    For experts

    Kisspeptin binds KISS1R (GPR54), a Gq/11-coupled receptor, and depolarises GnRH neurons. In adult mice kisspeptin depolarised more than 90% of GnRH neurons (Han 2005), and GPR54 mRNA colocalises with GnRH neurons; kisspeptin raised LH and FSH in wild-type but not Gpr54-null mice, and given into the brain of sheep it released GnRH into cerebrospinal fluid (Messager 2005). These direct-action data are from animals. In humans, biallelic inactivating KISS1R variants cause hypogonadotropic hypogonadism (Seminara 2003; de Roux 2003), and cryo-EM structures of KISS1R with kisspeptin-54 and kisspeptin-10 bound to Gq show the binding pocket (Science Advances 2024; Cell Reports 2024).[src][src][src][src][src][src]

  3. 03Brain

    GnRH tells the pituitary gland to release LH and FSH

    The switched-on cells send small pulses of a signal called GnRH to the pituitary gland, a pea-sized gland just under the brain. The pituitary answers by releasing two hormones called LH and FSH.

    For experts

    Pulsatile GnRH secretion into the hypophyseal portal circulation sets the pattern of LH and FSH secretion from pituitary gonadotropes. In healthy men, an intravenous kisspeptin-54 infusion raised mean 90-minute LH from 4.2 to 10.8 U/L and FSH from 3.2 to 3.9 U/L versus saline (Dhillo 2005). Consistent with an action above the pituitary, women with hypothalamic amenorrhoea still responded to GnRH after two weeks of kisspeptin-54 had blunted their response to kisspeptin (Jayasena 2009). GnRH itself gave a larger LH rise than kisspeptin-10 or -54 in healthy men (Jayasena 2015, as summarised by FDA).[src][src][src]

  4. 04Bloodstream

    LH and FSH travel in the blood, and kisspeptin itself fades fast

    LH and FSH travel in the blood to the ovaries or testes. Kisspeptin itself does not last long in the blood. Half of it is gone in about half an hour, or in a few minutes for the short version.

    For experts

    Plasma kisspeptin-54 had a half-life of 27.6 +/- 1.1 min, a metabolic clearance rate of 3.2 +/- 0.2 mL/kg/min and a volume of distribution of 128.9 +/- 12.5 mL/kg in healthy men (Dhillo 2005). Kisspeptin-10 half-life was about 4 minutes in men and women (Jayasena 2011, summarised in FDA's briefing). In women the LH response depends on cycle phase: it is largest in the pre-ovulatory phase and near zero in the follicular phase (Dhillo 2007). Rapid enzymatic breakdown and short half-lives are one reason synthetic analogues such as MVT-602 (previously TAK-448) were developed (FDA 2024).[src][src][src]

  5. 05Elsewhere

    The ovaries or testes respond

    In men, LH tells the testes to make testosterone. In women, a big burst of LH makes an egg finish maturing so it can be released. This is why kisspeptin has been studied in IVF.

    For experts

    In healthy men, kisspeptin-54 infusion raised mean 180-minute testosterone from 21.7 to 24.9 nmol/L (Dhillo 2005). In IVF, a single subcutaneous kisspeptin-54 injection after ovarian stimulation induced an LH surge and egg maturation in all dose groups of a 53-woman study, with clinical pregnancy in 12 of 53 (Jayasena 2014). In 60 women at high risk of OHSS, oocyte maturation occurred in 95% and no woman developed moderate, severe or critical OHSS (Abbara 2015). Adding a second injection raised the share with at least 60% oocyte yield from 45% to 71% (Abbara 2017). The analogue MVT-602 (previously TAK-448) produced LH surges of similar size and length to the natural mid-cycle surge in women (Abbara 2024). In men, sustained exposure to the same analogue (as TAK-448) suppressed testosterone to the castration range in phase 1 studies (MacLean 2014). Comparisons with established triggers were not part of these trials.[src][src][src][src][src][src][src]

  6. 06Brain

    With repeated exposure the response fades

    If the switch is pressed again and again, the receptor gets tired and stops answering. Scientists call this tachyphylaxis. It was seen in monkeys and in women who were given repeated doses for two weeks.

    For experts

    In three agonadal juvenile male rhesus monkeys, continuous infusion of metastin 45-54 (kisspeptin-10) produced an LH rise for about 3 h followed by a drop despite continued infusion, and a later bolus no longer raised LH while GnRH and NMDA boluses still did (Seminara 2006, animal data). In women with hypothalamic amenorrhoea, twice-daily kisspeptin-54 for two weeks reduced the maximal LH increment from 24.0 to 2.5 IU/L (Jayasena 2009). In healthy women, a week of follicular-phase dosing did not abolish cyclicity but shortened the cycle (Jayasena 2013). In monkeys, hourly low-dose pulses of kisspeptin-10 kept producing consistent LH responses over 48 h (Plant 2006, as summarised by FDA; animal data).[src][src][src][src]

  7. 07Brain

    Effects on brain areas linked to mood and attraction

    Kisspeptin also seems to act on parts of the brain linked to mood and attraction. In small brain-scan studies, it changed activity in these areas. Scientists do not yet know if this leads to any benefit for people.

    For experts

    In a double-blind crossover imaging study of 29 healthy men, kisspeptin-54 enhanced limbic activity in response to sexual and couple-bonding stimuli and attenuated negative mood (Comninos 2017). In a randomised crossover trial in premenopausal women with hypoactive sexual desire disorder (40 randomised, 32 completed), kisspeptin-54 infusion modulated brain responses to erotic videos and face attraction (Thurston 2022). These are small, mechanistic neuroimaging studies rather than trials of clinical benefit, and neither led to any approval or recommended use.[src][src]

For experts

The detail

Kisspeptin is the family of peptides encoded by KISS1 and processed from a precursor into kisspeptin-54 (metastin, precursor residues 68-121), -14, -13 and -10. They share a C-terminal Arg-Phe-NH2 end, and the shortest active form is kisspeptin-10. Kisspeptin-54 (about 5.8 kDa) was first isolated from human placenta as the endogenous ligand of the orphan receptor now called KISS1R (GPR54) (Ohtaki 2001). The receptor is Gq/11-coupled. Inactivating KISS1R variants cause congenital hypogonadotropic hypogonadism in humans and Gpr54-null mice (Seminara 2003; de Roux 2003), which established kisspeptin as an upstream gatekeeper of pulsatile GnRH secretion. Infundibular (arcuate) kisspeptin neurons that co-express neurokinin B and dynorphin are thought to drive the GnRH pulse generator, and in rodents a rostral (AVPV) kisspeptin population drives the pre-ovulatory LH surge. The molecule discussed here is the unmodified, native peptide, with no engineered half-life extension: kisspeptin-54 has a plasma half-life of about 28 minutes after intravenous infusion in men (Dhillo 2005) and kisspeptin-10 about 4 minutes (Jayasena 2011, as summarised by FDA). The synthetic analogue MVT-602 (previously TAK-448), a modified nonapeptide based on kisspeptin-10, is a separate substance: in two phase 1 studies sustained exposure lowered testosterone to the castration range in men (MacLean 2014), and in phase 1 and 2a trials in women its mean elimination half-life was 1.3-2.2 h (Abbara 2024). In humans, acute intravenous or subcutaneous kisspeptin-54 raises LH, FSH and, in men, testosterone (Dhillo 2005), with the largest LH response in the pre-ovulatory phase in women (Dhillo 2007). Repeated dosing over two weeks in women with hypothalamic amenorrhoea caused tachyphylaxis (Jayasena 2009), matching continuous-infusion desensitisation in monkeys (Seminara 2006). Phase 2 IVF studies at one London centre used a single injection of kisspeptin-54 to trigger oocyte maturation, including in women at high risk of ovarian hyperstimulation syndrome (Jayasena 2014; Abbara 2015, 2017). Intranasal kisspeptin-54 raised LH in a 2025 crossover study. No phase 3 trial exists. No product containing kisspeptin is approved by any regulator. FDA's October 2024 briefing found no approved product containing kisspeptin-10 in any country, and its 503A list, updated 14 May 2026, places kisspeptin-10 in Category 2 (substances raising significant safety concerns).

Evidence: Native kisspeptin-54 has been tested in small, supervised human studies: physiology studies in healthy volunteers and patients (usually 5 to 40 people), a few small randomised trials, and single-centre phase 2 IVF trials (53 and 60 women, plus a 62-woman randomised second-dose trial) in which one injection triggered egg maturation. A 2025 crossover study tested a nasal spray. There is no phase 3 trial and no regulatory approval for any indication. Repeated dosing has shown loss of response (tachyphylaxis) in women with hypothalamic amenorrhoea. FDA's 2024 review found the evidence insufficient to judge kisspeptin-10 for male hypogonadism, and no published clinical trial of kisspeptin-10 given for more than one day. Popular claims about weight loss, libido or fertility outside these studies are not established by trials.[src][src][src][src][src][src]

Known safety signals

  • FDA's interim 503A list, updated 14 May 2026, places kisspeptin-10 in Category 2, defined as bulk substances that raise significant safety concerns.[src]
  • Human safety data are limited to short, small studies. FDA's 2024 review found no clinical trial of kisspeptin-10 beyond one day of dosing, and no study of the intramuscular route. It saw no serious adverse events in those short studies, but many did not report adverse events.[src]
  • FDA raised concerns that injected kisspeptin-10 could provoke an immune response (including antibodies that might cross-react with the body's own kisspeptin), and that peptide impurities or clumping could add to this. No study has formally measured immunogenicity.[src]
  • Repeated dosing can stop working: in women with hypothalamic amenorrhoea, the LH response to twice-daily kisspeptin-54 fell sharply over two weeks (tachyphylaxis).[src]
  • Cell and animal-only signal: in cultured human vascular cells, and in a mouse model prone to atherosclerosis given kisspeptin-10 for four weeks, kisspeptin-10 promoted vascular inflammation and plaque growth. FDA called the human relevance unclear. FDA also noted that its nonclinical toxicity data were too limited to assess safety for clinical use.[src]
  • In a small 2025 crossover study, intranasal kisspeptin-54 caused no reported side effects or adverse events. One small study is not proof of safety for wider or long-term use.[src]

Around the world

Is Kisspeptin legal where you live?

CountryStatusWhat it meansVerified
AustraliaNot approvedNo kisspeptin product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
BrazilNot approvedNo Brazilian registration for kisspeptin; the unregistered-peptide rules applyDetails →source2026-09-29
CanadaProhibitedNot authorised; named in three Health Canada seizure notices (2025) and banned in sportDetails →source2026-09-29
ChinaNot approvedNo NMPA approval found for kisspeptin; it cannot lawfully be sold as a medicine in China.Details →source2026-09-29
European UnionNot approvedNo EU marketing authorisation; in sport, banned for males (WADA S2.2.1)Details →source2026-09-29
IndiaNot approvedNot approved in India: no CDSCO marketing permission found for Kisspeptin; making or selling it as a medicine would be unapprovedDetails →source2026-09-29
JapanNot approvedNot an approved medicine in Japan; kisspeptin is absent from PMDA's lists, and WADA bans it in sportDetails →source2026-09-29
MexicoNot approvedNo registration for kisspeptin found in COFEPRIS listsDetails →source2026-09-29
New ZealandProhibitedNot approved; Medsafe names kisspeptin as an illegal unapproved peptide and says it seizes itDetails →source2026-09-29
United Arab EmiratesNot approvedNot approved in the UAE: no marketing authorisation for kisspeptin; unapproved peptide products are under EDE enforcementDetails →source2026-09-29
United KingdomNot approvedKisspeptin is not licensed in the UKDetails →source2026-09-29
United StatesNot approvedNo FDA approval; kisspeptin-10 is in FDA's 503A Category 2 because of immunogenicity and missing safety dataDetails →source2026-09-29

Recent history

  1. 2023-09-29

    FDA lists several peptides, including ipamorelin and kisspeptin-10, in 'Category 2' of its compounding bulk-substances process

Full timeline →

Related molecules

Sources (71)

  1. 01Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human malesJournal of Clinical Endocrinology and Metabolism (Dhillo WS et al.) · 2005-12 · accessed 2026-09-29
  2. 02Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilizationJournal of Clinical Investigation (Jayasena CN et al.) · 2014-08 · accessed 2026-09-29
  3. 03Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) TherapyJournal of Clinical Endocrinology and Metabolism (Abbara A et al.) · 2015-09 · accessed 2026-09-29
  4. 04A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialHuman Reproduction (Abbara A et al.) · 2017-09-01 · accessed 2026-09-29
  5. 05Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humanseBioMedicine (Mills EG et al.) · 2025-05 · accessed 2026-09-29
  6. 06FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, October 29, 2024: Evaluation of Kisspeptin-10 for Inclusion on the 503A Bulk Drug Substances ListU.S. Food and Drug Administration · 2024-10 · accessed 2026-09-29
  7. 07Kisspeptin and neurokinin B: roles in reproductive healthPhysiological Reviews (Koysombat K et al.) · 2025-04-01 · accessed 2026-09-29
  8. 08Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54Proceedings of the National Academy of Sciences (Messager S et al.) · 2005-02-01 · accessed 2026-09-29
  9. 09Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of pubertyJournal of Neuroscience (Han SK et al.) · 2005-12-07 · accessed 2026-09-29
  10. 10The GPR54 gene as a regulator of pubertyNew England Journal of Medicine (Seminara SB et al.) · 2003-10-23 · accessed 2026-09-29
  11. 11Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54Proceedings of the National Academy of Sciences (de Roux N et al.) · 2003-09-16 · accessed 2026-09-29
  12. 12Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptorScience Advances (2024) · 2024-08-16 · accessed 2026-09-29
  13. 13Structural basis for hormone recognition and distinctive Gq protein coupling by the kisspeptin receptorCell Reports (Shen S et al.) · 2024-07-23 · accessed 2026-09-29
  14. 14Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxisJournal of Clinical Endocrinology and Metabolism (Jayasena CN et al.) · 2009-11 · accessed 2026-09-29
  15. 15Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in womenJournal of Clinical Endocrinology and Metabolism (Dhillo WS et al.) · 2007-10 · accessed 2026-09-29
  16. 16Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical trialsFertility and Sterility (Abbara A et al.) · 2024-01 · accessed 2026-09-29
  17. 17Kisspeptin receptor agonist has therapeutic potential for female reproductive disordersJournal of Clinical Investigation (Abbara A et al.) · 2020-12-01 · accessed 2026-09-29
  18. 18Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studiesJournal of Clinical Endocrinology and Metabolism (MacLean DB et al.) · 2014-08 · accessed 2026-09-29
  19. 19Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implicationsEndocrinology (Seminara SB et al.) · 2006-05 · accessed 2026-09-29
  20. 20Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteersJournal of Clinical Endocrinology and Metabolism (Jayasena CN et al.) · 2013-11 · accessed 2026-09-29
  21. 21Kisspeptin modulates sexual and emotional brain processing in humansJournal of Clinical Investigation (Comninos AN et al.) · 2017-02-01 · accessed 2026-09-29
  22. 22Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical TrialJAMA Network Open (Thurston L et al.) · 2022-10-03 · accessed 2026-09-29
  23. 23Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptorNature (Ohtaki T et al.) · 2001-05-31 · accessed 2026-09-29
  24. 24Kisspeptin (PubChem CID 71306396)PubChem, National Center for Biotechnology Information · 2026 · accessed 2026-09-29
  25. 25Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026)U.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
  26. 26ARTG keyword search for 'kisspeptin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  27. 27Understanding your responsibilities when importing, compounding and supplying unapproved peptide productsTherapeutic Goods Administration (TGA) · 2026-04-13 · accessed 2026-09-29
  28. 28TGA strengthens compliance focus on unapproved peptide products as part of evolving risk responseTherapeutic Goods Administration (TGA) · 2026-06-10 · accessed 2026-09-29
  29. 29Dados abertos: registro de medicamentos (DADOS_ABERTOS_MEDICAMENTOS.csv)Agência Nacional de Vigilância Sanitária (Anvisa) · 2026-09-29 · accessed 2026-09-29
  30. 30Checamos: peptídeos que prometem milagres NÃO estão registrados na AnvisaAgência Nacional de Vigilância Sanitária (Anvisa) · 2026-07-02 · accessed 2026-09-29
  31. 31Drug Product Database API: active-ingredient search for kisspeptinHealth Canada (Drug Product Database) · 2026-09-29 · accessed 2026-09-29
  32. 32Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874)Health Canada · 2026-04-09 · accessed 2026-09-29
  33. 33World Anti-Doping Code International Standard: Prohibited List 2026World Anti-Doping Agency · 2025-09 · accessed 2026-09-29
  34. 34Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks (RA-77218)Health Canada · 2025-04-02 · accessed 2026-09-29
  35. 35Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks (RA-77807)Health Canada · 2025-08-01 · accessed 2026-09-29
  36. 36Unauthorized health products sold online and seized at Rize Fitness may pose serious health risksHealth Canada · 2025-12-24 · accessed 2026-09-29
  37. 37Drug Administration Law of the PRC (中华人民共和国药品管理法)National Medical Products Administration (NMPA) · 2019-08-26 · accessed 2026-09-29
  38. 38Provisions for Drug Registration (SAMR Order No. 27; 药品注册管理办法)State Administration for Market Regulation (SAMR) · 2020-01-22 · accessed 2026-09-29
  39. 39CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29
  40. 40EMA medicines data (JSON report): human and veterinary medicines, with authorisation statusEuropean Medicines Agency · 2026-09-29 · accessed 2026-09-29
  41. 41Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text, 1 January 2025)European Union (EUR-Lex) · 2025-01-01 · accessed 2026-09-29
  42. 42Manufacturing and marketing of unapproved drug products containing Enclomiphene and its combinations (sets out the New Drugs rule for unapproved products)Central Drugs Standard Control Organisation (CDSCO) · 2026-08-10 · accessed 2026-09-29
  43. 43CDSCO Subject Expert Committee (SEC) recommendations index (records reviewed 2015 to September 2026)Central Drugs Standard Control Organisation (CDSCO) · 2026-09-23 · accessed 2026-09-29
  44. 44Public Notice dated 18 May 2026: injectable preparations do not fall under the definition of cosmeticsCentral Drugs Standard Control Organisation (CDSCO) · 2026-05-18 · accessed 2026-09-29
  45. 45Approved new drugs list (Japanese), fiscal 2026 to date, covering approvals from May to September 2026 (承認品目一覧(新医薬品))Pharmaceuticals and Medical Devices Agency (PMDA) · 2026-09 · accessed 2026-09-29
  46. 46List of Approved Drugs, April 2004 to February 2026 (new drugs)Pharmaceuticals and Medical Devices Agency (PMDA) · 2026 · accessed 2026-09-29
  47. 47Prescription drug package insert and review report search (医療用医薬品 添付文書等情報検索)Pharmaceuticals and Medical Devices Agency (PMDA) · 2026-09-29 · accessed 2026-09-29
  48. 48Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act), consolidated textDigital Agency (e-Gov Law Search) · 2026-05-21 · accessed 2026-09-29
  49. 49Personal import of pharmaceuticals and related products (医薬品等の個人輸入について)Ministry of Health, Labour and Welfare (MHLW) · 2025 · accessed 2026-09-29
  50. 50Japan Anti-Doping Agency (JADA) websiteJapan Anti-Doping Agency (JADA) · 2026 · accessed 2026-09-29
  51. 51Registros sanitarios de medicamentos alopáticos expedidos 2026COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2026-08-04 · accessed 2026-09-29
  52. 52Listados de registros sanitarios de medicamentos (visor y listas anuales)COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2025-08-21 · accessed 2026-09-29
  53. 53Solicitudes de medicamentos (excepto genérico y biocomparable) ingresadas en 2026COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2026-08-31 · accessed 2026-09-29
  54. 54Alerta sanitaria: comercialización ilegal de productos con tirzepatida sin registro sanitarioCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2026-02-09 · accessed 2026-09-29
  55. 55Consumer advisory: Unapproved peptide products health warningMedsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-05-21 · accessed 2026-09-29
  56. 56Medicines Classification Database (Schedule 1, Medicines Regulations 1984)Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-09-25 · accessed 2026-09-29
  57. 57Data sheets index (medicines with consent to be distributed in New Zealand)Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-09-29 · accessed 2026-09-29
  58. 58Medicines Act 1981 (version as at 10 July 2026)New Zealand Parliamentary Counsel Office · 2026-07-10 · accessed 2026-09-29
  59. 59UAE cracks down on illegal weight-loss products, targets 71 violatorsKhaleej Times · 2026-07-25 · accessed 2026-09-29
  60. 60UAE weight-loss drug crackdown: 71 sources, 14 influencers face actionGulf News · 2026-07-25 · accessed 2026-09-29
  61. 61Pharmaceutical licensing and drug registration in the UAE (Federal Decree-Law 38 of 2024)Kayrouz and Associates · 2026-03-18 · accessed 2026-09-29
  62. 62Abu Dhabi health authority launches online form for reporting side effects from peptide productsEmirates 24|7 · 2026-09-25 · accessed 2026-09-29
  63. 63Federal Decree-Law No. (38) of 2024 on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments (Arabic text)Emirates Drug Establishment (EDE) · 2024-10-01 · accessed 2026-09-29
  64. 64Find product information about medicines (MHRA Products register)Medicines and Healthcare products Regulatory Agency (MHRA) · 2026-09-25 · accessed 2026-09-29
  65. 65The Human Medicines Regulations 2012, regulation 46 (prohibition on sale or supply of unauthorised medicinal products)UK Government (legislation.gov.uk) · 2012 · accessed 2026-09-29
  66. 66Borderline products: how to tell if your product is a medicineMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-07-02 · accessed 2026-09-29
  67. 67Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicinesMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-05-29 · accessed 2026-09-29
  68. 68MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicinesMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-02-25 · accessed 2026-09-29
  69. 69Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 and withdrawn nominations)U.S. Food and Drug Administration · 2026-04-22 · accessed 2026-09-29
  70. 70Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3)U.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
  71. 71Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29